Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 18/20 | 1.00 |
| ▸ | BCL2 | P10415 | 12/20 | 1.00 |
| ▸ | MCL1 | Q07820 | 12/20 | 1.00 |
| ▸ | BCL2A1 | Q16548 | 8/20 | 1.00 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.45 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.44 |
| ▸ | LDHA | P00338 | 1/20 | 0.41 |
| ▸ | LDHB | P07195 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1892776 | 0.88 | BCL2L1 (0.79) | BCL2L1BCL2MCL1BCL2A1BCL2L2 | |
| SCHEMBL2532050 | 0.87 | BCL2L1 (0.76) | BCL2L1BCL2MCL1BCL2A1BCL2L2 | |
| SCHEMBL14995965 | 0.80 | BCL2L1 (0.66) | BCL2L1BCL2MCL1BCL2A1BCL2L2 | |
| SCHEMBL14995970 | 0.78 | BCL2L1 (0.64) | BCL2L1BCL2MCL1BCL2A1BCL2L2 | |
| SCHEMBL30428669 | 0.76 | BCL2L1 (0.63) | BCL2L1BCL2MCL1BCL2A1BCL2L2 | |
| SCHEMBL2622283 | 0.76 | BCL2L1 (0.60) | BCL2L1BCL2MCL1BCL2A1BCL2L2 | |
| SCHEMBL2528280 | 0.76 | BCL2L1 (0.61) | BCL2L1BCL2MCL1BCL2A1BCL2L2 | |
| SCHEMBL3475235 | 0.74 | BCL2L1 (1.00) | BCL2L1BCL2MCL1BCL2A1BAK1 | |
| SCHEMBL353855 | 0.73 | BCL2L1 (1.00) | BCL2L1BCL2MCL1BCL2A1BAK1 | |
| SCHEMBL2529200 | 0.72 | BCL2L1 (0.58) | BCL2L1BCL2MCL1BCL2A1BCL2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2418942-B1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | SANFORD-BURNHAM MEDICAL RES INST (US) | 2017-08-23 | — | — | EP | disclosed |
| US-8039668-B2 | Naphthalene-based inhibitors of anti-apoptotic proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2011-10-18 | — | — | US | disclosed |
| US-20100267781-A1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267781-A1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | HAX1, BAX, APOL1 | BCL2L1 20/4885BCL2 11/4885MCL1 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.